我是 LongbridgeAI，我可以總結文章信息。Amylyx Pharmaceuticals (AMLX) 的股價飆升 64%，創下歷史新高，此前其針對減肥手術後低血糖的治療藥物 avexitide 的晚期 LUCIDITY 試驗數據表現積極。該藥物將嚴重低血糖事件減少了 55%，且安全性良好。在這一消息發佈後，Amylyx 啓動了 3.5 億美元的公開募股，以資助商業化和研發工作。H.C. Wainwright、Stifel 和 Citi 的分析師提高了目標價，並維持買入評級，稱其審批前景風險降低
・AMLX’s Tuesday rally followed positive topline data from the late-stage LUCIDITY study of avexitide, a once-daily injection for post-bariatric hypoglycemia. ・H.C. Wainwright raised its price target on Amylyx to $55 from $34 and kept a Buy rating following the trial data unveiling. ・Stifel called the clinical data a “best-case scenario” and “clear ...